Fulgent Genetics Finalizes Strategic Acquisitions of Bako Diagnostics and StrataDx, Advancing Its Precision Medicine Ambitions

Key Highlights

• Fulgent Genetics, Inc. (NASDAQ: FLGT) has completed the acquisition of Bako Diagnostics and StrataDx, first announced on December 22, 2025.
• Total combined purchase price: approximately \$56.9 million in cash, subject to post-closing adjustments.
• The acquisitions enhance Fulgent’s presence in pathology and dermatopathology laboratory services, expanding its reach and capabilities in specialty laboratory testing.
• Strategic advisors: Piper Sandler & Co. (financial advisor) and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (legal counsel) for Fulgent; EV Health Partners (financial advisor) and Latham & Watkins LLP (legal counsel) for Consonance Capital Partners, Bako Diagnostics, and StrataDx.

Details of the Transactions

Under the terms of the agreement, Fulgent acquired certain assets of Bako Diagnostics and acquired StrataDx outright. The all-cash transaction, totaling approximately \$56.9 million, further solidifies Fulgent’s commitment to becoming a fully integrated precision medicine company by adding complementary capabilities in anatomic pathology, molecular genetic testing, and dermatopathology.

About the Acquired Companies

Bako Diagnostics

• A premier national provider of specialty laboratory testing services,
• Offers a comprehensive menu including anatomic pathology, proprietary molecular genetic testing, and peripheral neuropathy immuno-histochemical testing,
• Focused on unmatched sector expertise and physician support services.

StrataDx

• National diagnostic laboratory located in Lexington, Massachusetts,
• Specializes in advanced dermatopathology services for a wide range of skin conditions, including melanocytic and soft tissue lesions, dermatoses, and lymphomas,
• Board-certified oral pathologists and dermatopathology experts with decades of experience,
• Recognized as a leader in dermatology market testing.

Strategic Impact and Shareholder Considerations

• Expansion of Service Offerings: These acquisitions significantly broaden Fulgent’s testing and laboratory service portfolio, reinforcing its position in the specialty pathology and dermatopathology markets.
• Growth in Precision Medicine: The move aligns with Fulgent’s vision to transition from a diagnostic business to a fully integrated precision medicine company, leveraging innovative nanoencapsulation and targeted therapy platforms for cancer treatment.
• Potential for Revenue Diversification and Margin Enhancement: With the addition of Bako and StrataDx, Fulgent expects to access new customer segments and revenue streams, which could improve its financial profile and reduce dependence on a concentrated customer base.
• Integration Risks: Investors should be aware that the success of these acquisitions depends on Fulgent’s ability to integrate the new businesses efficiently, maintain turnaround times, preserve margins, and achieve intended synergies. There are also risks related to technology evolution, reimbursement rates, and compliance with complex regulations.
• Financial Disclosure: The transaction was an all-cash deal, which may impact short-term liquidity but demonstrates Fulgent’s financial strength and commitment to strategic growth.

Forward-Looking Statements and Risks

The company notes that this press release contains forward-looking statements, including expectations for future growth, expansion, integration of acquired businesses, and the potential benefits of research and development activities. These statements are subject to numerous risks, such as integration challenges, market adoption rates, reimbursement issues, regulatory compliance, volatility in operating results, and protection of intellectual property. Investors are cautioned that actual results may differ materially from those indicated in these statements, and Fulgent assumes no obligation to update these statements except as required by law.

Investor Relations Contact

For further information, investors may contact:
The Blueshirt Group
Lauren Sloane, [email protected]

Conclusion

These acquisitions are highly significant for Fulgent Genetics and could be a major catalyst for share price movement. The company’s expansion into new specialty testing markets and its strategic positioning in precision medicine represent important developments for current and potential shareholders.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties as detailed in Fulgent Genetics’ filings with the SEC.

View Fulgent Genetics, Inc. Historical chart here